A Multi Centre, Single Arm, Observational Study on Safety and Efficacy of MabThera Plus Chemotherapy as 1st Line Treatment in Patients With DLBCL or FL

Trial Profile

A Multi Centre, Single Arm, Observational Study on Safety and Efficacy of MabThera Plus Chemotherapy as 1st Line Treatment in Patients With DLBCL or FL

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Rituximab (Primary) ; Antineoplastics
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 01 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 04 Apr 2016 Planned End Date changed from 1 Oct 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
    • 04 Apr 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top